Killer immunoglobulin-like receptors (KIR2DL2 and/or KIR2DS2) in presence of their ligand (HLA-C1 group) protect against chronic myeloid leukaemia

Tissue Antigens

Volumn 73, Issue 6, 2009, Pages 553-560

  Middleton, D ^a   Diler, A S ^b   Meenagh, A ^c   Sleator, C ^c   Gourraud, P A ^d,e  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ISTANBUL UNIVERSITY   (Turkey)

^c BELFAST CITY HOSPITAL   (United Kingdom)

^d UNIVERSITÉ DE TOULOUSE   (France)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Human leucocyte antigen ligands; Killer immunoglobulin like receptors; Leukaemia

Indexed keywords

HLA B ANTIGEN; HLA BW4 ANTIGEN; HLA BW6 ANTIGEN; HLA C ANTIGEN; HLA C1 ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DS2; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER SUSCEPTIBILITY; CHILD; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HOMOZYGOSITY; HOST RESISTANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TURKEY (REPUBLIC);

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HLA-C ANTIGENS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTORS, KIR; RECEPTORS, KIR2DL2; YOUNG ADULT;

EID: 65649086742     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2009.01235.x     Document Type: Article

References (22)

1. Verheyden S, Demanet C. NK cell receptors and their ligands in leukemia. Leukemia 2008 : 22 : 249 57.
2. Demanet C, Mulder A, Deneys V et al. Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack? Blood 2004 : 103 : 3122 30. (Pubitemid 38451690)
3. Brouwer RE, van der Heiden P, Schreuder GM et al. Loss or downregulation of HLA class I expression at the allelic level in acute leukemia is infrequent but functionally relevant, and can be restored by interferon. Hum Immunol 2002 : 63 : 200 10. (Pubitemid 34246053)
4. Vollmer M, Li L, Schmitt A et al. Expression of human leucocyte antigens and co-stimulatory molecules on blasts of patients with acute myeloid leukaemia. Br J Haematol 2003 : 120 : 1000 8. (Pubitemid 36411559)
5. Smyth MJ, Swann J, Cretney E, Zerafa N, Yokoyama WM, Hayakawa Y. NKG2D function protects the host from tumor initiation. J Exp Med 2005 : 202 : 583 8. (Pubitemid 41248410)
6. Middleton D, Gonzalez A, Gilmore PA. Studies on the expression of the deleted KIR2DS4*003 gene product and distribution of KIR2DS4 deleted and nondeleted versions in different populations. Hum Immunol 2008 : 68 : 128 34. (Pubitemid 46282218)
7. Ruggeri L, Capanni M, Casucci M et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999 : 94 : 333 9. (Pubitemid 29300166)
8. Ruggeri L, Capanni M, Urbani E et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002 : 295 : 2097 100. (Pubitemid 34229476)
9. Gustincich S, Manfioletti G, Del Sal G, Schneider C, Carninci P. A fast method for high-quality genomic DNA extraction from whole human blood. Biotechniques 1991 : 11 : 298 300.
10. Mendez A, Granda H, Meenagh A et al. Study of KIR genes in tuberculosis patients. Tissue Antigens 2006 : 68 : 386 9.
11. Middleton D, Curran MD, Maxwell L. Natural killer cells and their receptors. Transpl Immunol 2002 : 10 : 147 64.
12. Middleton D, Williams F, Halfpenny IA. KIR genes. Transpl Immunol 2005 : 14 : 135 42. (Pubitemid 40848518)
13. Middleton D, Vilchez JR, Cabrera T et al. Analysis of KIR gene frequencies in HLA class I characterized bladder, colorectal and laryngeal tumours. Tissue Antigens 2007 : 69 : 220 6. (Pubitemid 46696942)
14. Middleton D, Meenagh A, Gourraud PA. KIR haplotype content at the allele level in 77 Northern Irish families. Immunogenetics 2007 : 59 : 145 58. (Pubitemid 46130793)
15. Benjamini Y, Yekutieli D. The control of the false discovery rate in multiple testing under dependency. Ann Stat 2001 : 29 : 1165 88. (Pubitemid 33000466)
16. Verheyden S, Bernier M, Demanet C. Identification of natural killer cell receptor phenotypes associated with leukemia. Leukemia 2004 : 18 : 2002 7. (Pubitemid 40028427)
17. Verheyden S, Demanet C. Susceptibility to myeloid and lymphoid leukemia is mediated by distinct inhibitory KIR-HLA ligand interactions. Leukemia 2006 : 20 : 1437 8. (Pubitemid 44084059)
18. Single RM, Martin MP, Gao X et al. Global diversity and evidence for coevolution of KIR and HLA. Nat Genet 2007 : 39 : 1114 9. (Pubitemid 47342436)
19. Cooley S, Trachtenberg E, Bergemann TL et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 2009 : 113 : 726 32.
20. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002 : 419 : 734 8. (Pubitemid 35177960)
21. Costello RT, Sivori S, Marcenaro E et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 2002 : 99 : 3661 7. (Pubitemid 34286018)
22. Carosella ED, Moreau P, LeMaoult J, Rouas-Freiss N. HLA-G: from biology to clinical benefits. Trends Immunol 2008 : 29 : 125 32.